Medical Products and Capabilities Enhancement Activities

Abstract

Guidance for Development of the Force-Medical Products and Capabilities Enhancement Activities: Funds will support (1) developmental upgrades to medical systems and products that have been fielded, are routinely used in a fixed facility, or that have been approved for full-rate production and for which procurement funding is anticipated in the current fiscal year or subsequent fiscal years, (2) testing and evaluation supporting the enhancement of fielded or procured medical systems/products and medically-related information technology systems, (3) assessment of fielded medical products or medical practices in order to identify the need/opportunity for changes, and (4) analyses of clinical intervention outcomes to enhance and improve military unique Clinical Practice Guidelines. Efforts address the Military Health System Concept of Operations documents and follow-on Capabilities Based Assessments/Joint Capability Documents, appropriate Component requirements, legislative and Executive directives (e.g., National Research Action Plan, Precision Medicine Initiative, Office of Management and Budget Combat Casualty Care Assessment, National Defense Authorization Acts, etc.), and others as appropriate.

Open PDF

Document Details

Document Type
R2 Budgetary Justification
Publication Date
Oct 01, 2020
Source ID
0607100DHA_2_0130_PB_2020
Change Summary Explanation
FY 2016: Realignment from Defense Health Program, Research, Development, Test and Evaluation (DHP RDT&E), PE 0607100-Medical Products and Capabilities Enhancement Activities (-$1.304 million) to DHP RDT&E PE 0605502-Small Business Innovation Research (SBIR) / Small Business Technology Transfer (STTR) Program (+$1.304 million). FY 2017: Realignment from Defense Health Program, Research, Development, Test and Evaluation (DHP RDT&E), Program Element (PE) PE 0607100-Medical Products and Capabilities Enhancement Activities (-$2.291 million) to DHP O&M Account, Budget Activity Group (BAG) 3 - Private Sector Caree (+$2.291 million). FY 2017: Realignment from Defense Health Program, Research, Development, Test and Evaluation (DHP RDT&E), PE 0607100-Medical Products and Capabilities Enhancement Activities (-$0.358 million) to USU DHP RDT&E PE 0603115 Breast, GYN and Prostate Cancer Centers of Excellence (+$0.358 million). FY 2018: Realignment from DHP RDTE PE 0607100-Medical Products and Capabilities Enhancement Activities, Project 377 GDF (-$1.500 million) to DHP RDTE PE 0603115-Medical Technology Development, Uniformed Services University, Project 478 Applied Proteogenomics Organization Learning and Outcomes (APOLLO) Consortium (+$1.500 million) to support the White House-directed Cancer Moonshot initiative.
Service Agency Name
Defense Health Agency

Entities

Organizations

  • Defense Health Agency

Tags

DTIC Thesaurus Topics

  • Acquisition
  • Air Force
  • Air Force Procurement
  • Casualties
  • Combat Casualty Care
  • Commerce
  • Infectious Diseases
  • Information Systems
  • Military Medicine
  • National Security
  • Personalized Medicine
  • Procurement
  • Production
  • Prostate Cancer
  • Small Business
  • Technology Transfer
  • Test And Evaluation

Fields of Study

  • Medicine

Readers

  • Military Science and Technology Research and Modernization.
  • Naval Mine Countermeasure Systems Development.
  • Trauma or Military Medicine

Related Documents